Yanan Zhu
Stock Analyst at Wells Fargo
(2.16)
# 2,940
Out of 5,240 analysts
90
Total ratings
43.24%
Success rate
-4.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGX Metagenomi Therapeutics | Maintains: Overweight | $12 → $9 | $1.34 | +571.64% | 5 | May 12, 2026 | |
| ENGN enGene Therapeutics | Downgrades: Equal-Weight | $25 → $2 | $1.68 | +19.05% | 2 | May 8, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $95 → $105 | $77.67 | +35.19% | 2 | May 7, 2026 | |
| ONC BeOne Medicines AG | Initiates: Overweight | $400 | $303.67 | +31.72% | 1 | May 4, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Overweight | $50 → $90 | $75.86 | +18.65% | 4 | Apr 14, 2026 | |
| RNA Atrium Therapeutics | Initiates: Overweight | $25 | $13.25 | +88.68% | 5 | Mar 11, 2026 | |
| QURE uniQure | Upgrades: Overweight | $15 → $60 | $27.83 | +115.59% | 7 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $12 → $15 | $13.51 | +11.07% | 8 | Mar 3, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $45 → $38 | $19.04 | +99.58% | 8 | Feb 27, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $6.40 | +72.01% | 4 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $100 | $75.79 | +31.94% | 4 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $20 | $8.05 | +148.45% | 9 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $4 | $2.87 | +39.37% | 7 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $37.68 | +19.43% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $2.05 | +21.95% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.55 | +222.58% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $3.61 | +288.35% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $29.82 | +134.74% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.36 | +129.36% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $50.98 | +27.50% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.53 | +17,664.79% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $807.85 | -59.65% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.24 | +583.59% | 2 | Oct 29, 2020 |
Metagenomi Therapeutics
May 12, 2026
Maintains: Overweight
Price Target: $12 → $9
Current: $1.34
Upside: +571.64%
enGene Therapeutics
May 8, 2026
Downgrades: Equal-Weight
Price Target: $25 → $2
Current: $1.68
Upside: +19.05%
Cytokinetics
May 7, 2026
Maintains: Overweight
Price Target: $95 → $105
Current: $77.67
Upside: +35.19%
BeOne Medicines AG
May 4, 2026
Initiates: Overweight
Price Target: $400
Current: $303.67
Upside: +31.72%
Spyre Therapeutics
Apr 14, 2026
Maintains: Overweight
Price Target: $50 → $90
Current: $75.86
Upside: +18.65%
Atrium Therapeutics
Mar 11, 2026
Initiates: Overweight
Price Target: $25
Current: $13.25
Upside: +88.68%
uniQure
Mar 9, 2026
Upgrades: Overweight
Price Target: $15 → $60
Current: $27.83
Upside: +115.59%
Intellia Therapeutics
Mar 3, 2026
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $13.51
Upside: +11.07%
Sarepta Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $45 → $38
Current: $19.04
Upside: +99.58%
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $6.40
Upside: +72.01%
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $75.79
Upside: +31.94%
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $8.05
Upside: +148.45%
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.87
Upside: +39.37%
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $37.68
Upside: +19.43%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $2.05
Upside: +21.95%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.55
Upside: +222.58%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $3.61
Upside: +288.35%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $29.82
Upside: +134.74%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.36
Upside: +129.36%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $50.98
Upside: +27.50%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.53
Upside: +17,664.79%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $807.85
Upside: -59.65%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.24
Upside: +583.59%